Of note, this tumour-induced myeloid subset, characterized by the decreased expression of the DC marker CD1c and the concomitant acquisition of monocyte/TAM markers (CD14, CD163, CD206 and MerTK), is consistent with CD14+ DCs already described in literature in the context of cancer-related inflammation24,25. The gene discussed is MRC1; the disease is cancer.